Literature DB >> 15101560

Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide.

Thomas Walther1, Holger Stepan, Kristin Pankow, Matthias Becker, Heinz-Peter Schultheiss, Wolf-Eberhard Siems.   

Abstract

Recent reports presented contradictory results regarding the catabolism of mature atrial (ANP) and brain (BNP) natriuretic peptides in circulation. Especially the role of neutral endopeptidase (NEP) in BNP degradation was conversely discussed. Our present in vitro-studies characterize the NEP-dependent metabolism of ANP and BNP in different tissues via HPLC-analysis using NEP-deficient mice and specific NEP inhibitors. Our results show a strong tissue-dependent degradation pattern of both peptides, which are not only due to the different NEP activities in these tissues. Whereas NEP rapidly degraded ANP, it had no influence in BNP-metabolism. Additional experiments with purified NEP confirmed this result. Moreover, we describe a degradation of ANP and BNP in NEP-deficient- and NEP-inhibited membranes. Consequently, we postulate the existence of at least one further natriuretic peptide (NP) degrading enzyme, which has not been characterized yet. Thus, the commonly accepted model of the natriuretic peptide system with NEP as the central degrading peptidase has to be partly revised. Moreover, the NEP-independent BNP degradation provides an effective means for achieving a beneficial BNP increase in cardiovascular pathology by inhibiting the assumed novel NP-degrading peptidase(s).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101560     DOI: 10.1515/BC.2004.036

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Human B-type natriuretic peptide is not degraded by meprin A.

Authors:  Deborah M Dickey; Lincoln R Potter
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

2.  B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Authors:  Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-03-04       Impact factor: 24.094

3.  New function for an old enzyme: NEP deficient mice develop late-onset obesity.

Authors:  Matthias Becker; Wolf-Eberhard Siems; Reinhart Kluge; Florian Gembardt; Heinz-Peter Schultheiss; Michael Schirner; Thomas Walther
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

4.  BNP controls early load-dependent regulation of SERCA through calcineurin.

Authors:  Karl Toischer; Nils Teucher; Bernhard Unsöld; Michaela Kuhn; Harald Kögler; Gerd Hasenfuss
Journal:  Basic Res Cardiol       Date:  2010-08-15       Impact factor: 17.165

5.  The virtually mature B-type natriuretic peptide (BNP1-32) is a precursor for the more effective BNP1-30.

Authors:  Anja Schwiebs; Yong Wang; Andrew M Moore; Xudong Zhu; Kristin Pankow; Wolf-Eberhard Siems; Thomas Walther
Journal:  Br J Pharmacol       Date:  2020-02-19       Impact factor: 8.739

6.  Analytical Issues with Natriuretic Peptides - has this been Overly Simplified?

Authors:  Alexander G Semenov; Alexey G Katrukha
Journal:  EJIFCC       Date:  2016-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.